QUOTED. 11 August 2020. Bryan Hanson.
Most of the major orthopaedics companies beat analyst expectations in the second quarter, but the ongoing COVID-19 pandemic raises uncertainties regarding procedure volumes for the rest of this year. See what Zimmer Biomet’s CEO Bryan Hanson said about it here.
“Given the unknown numbers related to COVID, I would say it’s more prudent to be cautiously optimistic right now.” – Bryan Hanson, CEO, Zimmer Biomet
- Find out more: Orthopedics Roundup: Q2 Results Show Recovery In Elective Procedures; COVID-19 Uncertainties Remain
Click here for a free trial of Medtech Insight